Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Show more
Location: 170 Harbor Way, South San Francisco, CA, 94080, United States | Website: https://vaxart.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
102.2M
52 Wk Range
$0.26 - $1.07
Previous Close
$0.35
Open
$0.33
Volume
4,668,416
Day Range
$0.33 - $0.47
Enterprise Value
81.78M
Cash
41.94M
Avg Qtr Burn
-8.293M
Insider Ownership
1.06%
Institutional Own.
12.08%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VXA-CoV2-1 oral pill Details COVID-19 | Phase 2b Update | |
Monovalent Norovirus Vaccine Details Norovirus | Phase 2b Update | |
VXA-A1.1 Details Influenza | Phase 2 Update | |
Oral Bivalent Norovirus Vaccine Details Norovirus | Phase 2 Update | |
Oral Bivalent Norovirus Vaccine Details Norovirus | Phase 1 Update | |
Phase 1 Update |